MDVerse
Fremont
About MDVerse
MDVerse develops regenerative medicine for drug development, manufacturing, and clinical trials. The company uses disruptive technologies to help pharmaceutical companies, academic institutions, and clinical sites develop and deliver personalized, precision therapies more quickly and efficiently.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $750.0K
- Funding stage: Seed
- Last round: Seed (Jan 2023)
- Website: mdverse.io
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mdverse-105971 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.